NEW HAVEN, Conn., Nov. 14, 2022 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company using artificial intelligence approaches to develop transformative drugs in neuroscience and immuno-oncology, has announced today that Vimal Mehta, Ph.D., Founder and CEO, and Matt Wiley, Chief Commercial Officer, will participate in fireside chats at two upcoming investor conferences. Management will discuss the company’s neuroscience and immuno-oncology programs as well as its artificial intelligence platform used to augment and accelerate the process of discovery and development of drug candidates. They will also discuss the Company’s ongoing commercial launch strategy for the IGALMI™ (dexmedetomidine) sublingual film.
Presentation details:
Event: 4th Annual Guggenheim Immunology and Neurology Day
Date: Monday, November 14, 2022
Location: New York City
Time: 3:20 PM ET
Event: Jefferies 2022 Healthcare Conference in London
Date: Wednesday, November 16, 2022
Location: London
Time: 11:30 a.m. GMT, 6:30 a.m. ET
To access live webcasts of the Fireside Chats, please visit the Events/Presentation page on the Company’s website, www.bioxceltherapeutics.com, beginning 15 minutes prior to the start time of the presentations. Replays of the webcast will be available on the company’s website following the events.
About BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. is a biopharmaceutical company that uses artificial intelligence approaches to develop transformative drugs in neuroscience and immuno-oncology. The Company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates, as well as big data and proprietary machine learning algorithms to identify new therapeutic indices. The Company’s commercial product, IGALMI™ (developed as BXCL501), is a patented sublingual film formulation of dexmedetomidine approved for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adult. The safety and efficacy of IGALMI have not been established beyond 24 hours from the first dose. For more information, please visit IGALMIhcp.com and also see IGALMI’s full prescribing information. BXCL501 is being evaluated for home use for the acute treatment of agitation in bipolar and schizophrenic patients, for the acute treatment of agitation associated with probable Alzheimer’s disease, and as an adjunctive therapy for major depressive disorder. The safety and effectiveness of BXCL501 for these uses have not been established. The Company is also developing BXCL502 as a potential therapy for chronic agitation in dementia. Under its subsidiary OnkosXcel Therapeutics, the Company is developing BXCL701, an experimental systemic innate immune activator administered orally for the treatment of aggressive forms of prostate cancer. The safety and efficacy of BXCL502 and BXCL701 have not been established. For more information, please visit bioxceltherapeutics.com.
Forward-looking statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. We expect such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Private Securities Litigation Reform Act of securities. Act 1933, as amended (the “Securities Act”) and Section 21E of the Stock Exchanges Act 1934, as amended (the “Stock Exchanges Act”). All statements in this press release other than statements of historical facts should be considered forward-looking statements, including, without limitation, the dates, times and contents of the company’s fireside chats. at the 4th Annual Day of Immunology and Neurology at the Guggenheim and Jefferies 2022 Healthcare Conference in London. When used herein, words such as “anticipate”, “believe”, “may”, “continue”, “could”, “design”, “estimate”, “expect”, “expect”, “goal”, “intend”, “may”, “could”, “plan”, “possible”, “potential”, “predict”, “project”, “should”, “target”, “will” , “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements use these words or expressions. Further, any statement or information that refers to expectations, beliefs, plans, projections, goals, performance, or other characterizations of future events or circumstances, including any underlying assumptions, is forward-looking. . All forward-looking statements are based on the Company’s current expectations and various assumptions. The Company believes that there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not achieve its expectations and its beliefs may not prove to be accurate. Actual results could differ materially from those described or implied by these forward-looking statements due to various important factors, including, without limitation, the important factors discussed under the heading “Risk Factors” in its quarterly report on Form 10-Q for the quarter ended September 30, 2022, as such factors may be updated from time to time in its other filings with the SEC, which are accessible on the SEC’s website at www. .sec.gov. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. These forward-looking statements represent management’s estimates as of the date of this press release. Although the Company may elect to update these forward-looking statements at some time in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be taken to represent the views of the Company as of any date subsequent to the date of this press release.
Contact information
Company
BioXcel therapeutics
Erik Kopp
1.203.494.7062
ekopp@bioxceltherapeutics.com
Investor Relations
BioXcel therapeutics
Brennan Doyle
1.475.355.8462
bdoyle@bioxceltherapeutics.com
Media
FTI Council
Helen O’Gorman
1.718.408.0800
helen.ogorman@fticonsulting.com
Source: BioXcel Therapeutics, Inc.
#BioXcel #Therapeutics #Present #Upcoming #Investor #Conferences